Skip to content

ICAAC: Rapid HIV disease progression in injecting drug users in Ukraine

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: Kaletra: stability and potency decline rapidly in hot climates

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

ICAAC: Glaxo unveils chemokine blocker as interest in new drug class hots up

US HIV treatment guidelines revised

ICAAC: When to use T-20: new analysis shows risk of leaving it too late

ICAAC: Kaletra exposure decreased by tenofovir in experienced HIV patients

ICAAC: Tenofovir and Trizivir effective and well-tolerated in patients who fail first regimen